EVOLUTION DU PROCESSUS D
16 Pages
English
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

EVOLUTION DU PROCESSUS D'INNOVATION DANS LE ...

-

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer
16 Pages
English

Description

EVOLUTION DU PROCESSUS. D'INNOVATION DANS LE SECTEUR. PHARMACEUTIQUE. Reinhard Angelmar. Professeur de Marketing. INSEAD ...

Subjects

Informations

Published by
Reads 21
Language English

Exrait

EVOLUTION DU PROCESSUS D INNOVATION DANS LE SECTEUR PHARMACEUTIQUE
Reinhard Angelmar Professeur de Marketing INSEAD, Fontainebleau
Les réseaux mondiaux d innovation dans l industrie pharmaceutique IFRI, 16 mars 2006
INNOVATION PROCESS: MAIN PHASES AND CONTRIBUTORS
POST-REBSAESAIRCCHRAEPSPELAIRECDHDPERMVOEEDNLUTOCPT-CTLRIINIACLASLAPPROVALMVEAIRSLKLUEART-NICNEG
Public X Research
Small Biotech X Firms
Large Pharma X Firms
X
X
X
(X)
(X)
X
(X)
(X)
X
(X)
X
(X)
X
reinhard.angelmar@insead.edu
U.S. BIOMEDICAL RESEARCH FUNDING
Source: Moses et al., JAMA, 2005
reinhard.angelmar@insead.edu
R&D SPENDING BY SECTOR: EU TOP 500 COMPANIES, 2003
Sector FT classification
Sector R&D as a % of total
Sector R&D/Sales
reinhard.angelmar@insead.edu
DECLINING R&D PRODUCTIVITY
rei
nhard.angelmar@i
nsead.edu
PHARMACEUTICAL FIRM SPENDING BY R&D PHASE
31.9% of R&D
Source: PhRMA, 2005
Phase I: Phase II: 6.8% 11.1%
Phase III: 23.3%
Approval: Phase IV: 12% 10.7%
reinhard.angelmar@insead.edu
EVOLUTION OF PHARMA FIRM SPENDING BY R&D PHASE
1'100 1'000 900 800 700 600 500 400 300 200 100  -
Approval and regulatory Phase 4 Phase 1-3 Prehuman and preclinical
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Source: Moses et al., JAMA, Sept. 21, 2005 (based on PhRMA)
reinhard.angelmar@insead.edu
U.S. NME APPROVALS WITH PHASE IV COMMITMENTS
reinhard.angelmar@insead.edu
HOW TO INCREASE R&D PRODUCTIVITY?
INCREASE OUTPUT – Increase number of projects entering development – Reduce attrition – Increase in-licensing and acquisitions (no impact on industry output)
REDUCE COSTS – Reduce attrition in Phases II & III – Increase speed – Reduce cost per patient
reinhard.angelmar@insead.edu
Nr. OF ACTIVE DEVELOPMENT PROGRAMS
1800
1600
1400
1200
1000
800
600 400 200
0
Phase I Phase II Phase III
March 2001 March 2002 March 2003 March 2004 March 2005
Source: PARAXEL's Pharmaceutical R&D Statistical Sourcebook 2005/2006
reinhard.angelmar@insead.edu
REDUCE ATTRITION
Early prediction of efficacy (proof-of-concept) and safety
Portfolio management – First-in-class; best-in-class; me-too; line extensions
– R&D / strategy-marketing alignment
reinhard.angelmar@insead.edu